China
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced it presented four posters at the 25th World Congress of Dermatology being held in Singapore from July 3-8, 2023.
Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences
Sirnaomics Ltd. (the "Company", stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, hereby announces that Sirnaomics' Senior Director of Technology Innovation, Dr. Weterings will present the latest developments on its of GalAhead™, GalNAc-RNAi therapeutic platforms and related pipeline programs at international industry conferences taking place in July.
Zhongchao Inc. Partners with Ximalaya to Launch the First Audio Course Series for Cancer Education
Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that it cooperates with Shanghai Ximalaya Technology Co., Ltd. ("Ximalaya"), a widely popular Chinese online audio sharing platform in China, to launch the first series of audio courses dedicated to cancer education.
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab
Shanghai Junshi Biosciences Co., Ltd (HKEX: 1877; SSE: 688180) announced that the supplemental new drug application for toripalimab in combination with axitinib for the first-line treatment of patients with unresectable or metastatic renal cell carcinoma has been accepted by the National Medical Products Administration.
Clover Provides Updates on Business and R&D Pipeline Development
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today provided updates on business and R&D pipeline development.
BRONCUS COMPLETES THE FIRST CASE OF REGISTERED CLINICAL TRIALS OF ITS TARGETED LUNG DENERVATION RADIOFREQUENCY ABLATION SYSTEM
Broncus Holding Corporation (HKG:2216) has completed the first case of registered clinical trials of its targeted lung denervation (''TLD'') radiofrequency ablation system.
Doer Biologics Announces License Agreement with BioNTech
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a license agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech").
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and DualityBio, a next-generation ADC company, today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors.
Shineco Subsidiary Receives Marketing Approval from China’s Regulatory Body for its Cardiac 5-Minute Test
Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of technologically advanced healthcare products and services, announced today that on June 21, 2023, Changzhou Biowin Pharmaceutical Co., Ltd., a majority-owned subsidiary of the Company ("Biowin"), received marketing and distribution approval for its Cardiac 5-Minute Test from the Jiangsu Bureau of the National Medical Products Administration (“NMPA"), which is China’s regulatory equivalent of the U.S. Food and Drug Administration (FDA).
Jacobio Regains Global Rights to SHP2 Inhibitors
Jacobio announced that AbbVie has delivered the termination notice of the parties’ license and collaboration agreement (the “Agreement”) for the global development and commercialization of SHP2 inhibitors licensed by Jacobio to AbbVie under the Agreement, as part of AbbVie’s overall strategic decisions on its portfolio priorities
